AGLE

Aeglea Biotherapeutics, Inc.

No insider bought or sold Aeglea Biotherapeutics, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

Follow AGLE

AGLE over the last year

Prices for AGLE aren't in yet.

AGLE after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

20 insider filings since 2016, newest first

AGLEBuy

Marcio Souza · Director

$50KAug 25

AGLEBuy

Anthony G. Quinn · President and CEO

$188K+11.0%Mar 18

AGLEBuy

Anthony G. Quinn · President and CEO

$281K+24.0%Mar 15

AGLEBuy

Jonathan Alspaugh · CFO

$156K+83.0%Mar 15

AGLEBuy

Jonathan Alspaugh · CFO

$263KAug 18

AGLEBuy

Anthony G. Quinn · President and CEO

$784K+44.0%May 4

AGLEBuy

Anthony G. Quinn · President and CEO

$196K+10.0%Jun 14

AGLEBuy

Anthony G. Quinn · President and CEO

$180K+9.0%May 22

AGLEBuy

Anthony G. Quinn · President and CEO

$126K+7.0%May 17

AGLESell

Aaron Schuchart · Chief Business Officer

$57K−71.0%Sep 28

AGLESell

Novartis Bioventures Ltd · 10% owner

$197K−1.0%May 14

AGLESell

Novartis Bioventures Ltd · 10% owner

$748K−3.0%May 11

AGLESell

Novartis Bioventures Ltd · 10% owner

$424K−2.0%May 9

AGLEBuy

Anthony G. Quinn · Interim CEO

$41K+31.0%Dec 8

AGLEBuy

Charles N York II · CFO and VP

$116K+294.0%Dec 5

AGLEBuy

Anthony G. Quinn · Director

$83K+171.0%Dec 5

AGLEBuy

Eli & Co Lilly · 10% owner

$5.0M+24.0%Apr 14

AGLEBuy

Novartis Bioventures Ltd · 10% owner

$3.0M+15.0%Apr 12

AGLEBuy

Russell J. Cox · Director

$70KApr 12

AGLEBuy

Anthony Quinn · Director

$100KApr 12

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.